Literature DB >> 25217091

MicroRNA polymorphisms as markers of risk, prognosis and treatment response in hematological malignancies.

Agnieszka Dzikiewicz-Krawczyk1.   

Abstract

MicroRNA dysregulation is a common event in hematological malignancies. Apart from genomic and epigenetic alterations, miRNA networks may be disturbed by polymorphisms in the miRNA regulatory pathway (miRSNPs). In this review we provide an overview of three categories of miRSNPs: (1) SNPs in genes involved in miRNA biogenesis and processing; (2) SNPs in miRNA genes; and (3) SNPs in miRNA binding sites in target genes and discuss their potential role as markers of disease risk, prognosis and treatment response in hematological cancers. Although so far only the tip of the iceberg has been touched, studies of polymorphisms in the miRNA regulatory pathways have already provided some clues for the mechanisms of miRNA dysregulation in cancer and open new perspectives in the management of hematological malignancies.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Diagnosis; Hematological malignancies; MiRSNP; MicroRNA; Polymorphism; Prognosis; Treatment response

Mesh:

Substances:

Year:  2014        PMID: 25217091     DOI: 10.1016/j.critrevonc.2014.08.006

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  10 in total

Review 1.  Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction.

Authors:  Christian Schulte; Dirk Westermann; Stefan Blankenberg; Tanja Zeller
Journal:  World J Cardiol       Date:  2015-12-26

Review 2.  microRNA-based diagnostics and therapy in cardiovascular disease-Summing up the facts.

Authors:  Christian Schulte; Tanja Zeller
Journal:  Cardiovasc Diagn Ther       Date:  2015-02

Review 3.  A network-biology perspective of microRNA function and dysfunction in cancer.

Authors:  Cameron P Bracken; Hamish S Scott; Gregory J Goodall
Journal:  Nat Rev Genet       Date:  2016-10-31       Impact factor: 53.242

4.  High Resolution Melting Analysis for Evaluation of mir-612 (Rs12803915) Genetic Variant with Susceptibility to Pediatric Acute Lymphoblastic Leukemia.

Authors:  Payam Siyadat; Hossein Ayatollahi; Mahmood Barati; Maryam Sheikhi; Minoo Shahidi
Journal:  Rep Biochem Mol Biol       Date:  2021-01

Review 5.  Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma.

Authors:  Gabrielle Bradshaw; Heidi G Sutherland; Larisa M Haupt; Lyn R Griffiths
Journal:  Genes (Basel)       Date:  2016-12-17       Impact factor: 4.096

Review 6.  MiRNAs and miRNA Polymorphisms Modify Drug Response.

Authors:  Mu-Peng Li; Yao-Dong Hu; Xiao-Lei Hu; Yan-Jiao Zhang; Yong-Long Yang; Chun Jiang; Jie Tang; Xiao-Ping Chen
Journal:  Int J Environ Res Public Health       Date:  2016-11-08       Impact factor: 3.390

7.  miR-618 rs2682818 C>A polymorphism decreases Hirschsprung disease risk in Chinese children.

Authors:  Yi Zheng; Tongyi Lu; Xiaoli Xie; Qiuming He; Lifeng Lu; Wei Zhong
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

8.  Single Nucleotide Polymorphisms in MIR143 Contribute to Protection Against Non-Hodgkin Lymphoma (NHL) in Caucasian Populations.

Authors:  Gabrielle Bradshaw; Larisa M Haupt; Eunise M Aquino; Rodney A Lea; Heidi G Sutherland; Lyn R Griffiths
Journal:  Genes (Basel)       Date:  2019-02-27       Impact factor: 4.096

Review 9.  The Role of Exportin-5 in MicroRNA Biogenesis and Cancer.

Authors:  Ke Wu; Juan He; Wenchen Pu; Yong Peng
Journal:  Genomics Proteomics Bioinformatics       Date:  2018-04-30       Impact factor: 7.691

10.  The CCR4-NOT complex maintains liver homeostasis through mRNA deadenylation.

Authors:  Akinori Takahashi; Toru Suzuki; Shou Soeda; Shohei Takaoka; Shungo Kobori; Tomokazu Yamaguchi; Haytham Mohamed Aly Mohamed; Akiko Yanagiya; Takaya Abe; Mayo Shigeta; Yasuhide Furuta; Keiji Kuba; Tadashi Yamamoto
Journal:  Life Sci Alliance       Date:  2020-04-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.